title: How we manage persons with hereditary angioedema.
abstract: Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder clinically characterized by recurrent attacks of subcutaneous and mucosal swelling that can result in significant morbidity and even mortality. Several novel therapies introduced since 2008 have dramatically transformed the approach to management. In this review we will discuss the current understanding of the pathophysiology of HAE, diagnostic evaluation of recurrent angioedema without urticaria, and the therapeutic approach to HAE. We advocate taking an integrative approach to care in order to normalize the lives of affected patients.
authors.affiliation: University of California, San Diego, La Jolla, CA, USA.|San Diego VA Health System, San Diego, CA, USA.
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Zuraw
authors.affiliation: University of California, San Diego, La Jolla, CA, USA.
authors.forename: Sandra C
authors.initials: SC
authors.lastname: Christiansen
mesh_terms: D000293:Adolescent; D000328:Adult; D054179:Angioedemas, Hereditary / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D002648:Child; D019468:Disease Management; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D055815:Young Adult
keywords: C1 inhibitor; Hereditary angioedema; Management; bradykinin; treatment